Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia

World Journal of Hepatology

Volumn 2, Issue 5, 2010, Pages 180-184

  Issa, Hussain ^a  

^a KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

Chronic hepatitis C; Sickle cell anemia; Treatment

Indexed keywords

EID: 84867302369     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v2.i5.180     Document Type: Article

References (27)

1. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med 1978; 88: 1-6
2. Al-Awamy BH. Sickle cell anemia.its clinical manifestations and their management. Saudi Med J 1987; 9: 553-562
3. Krauss JS, Freant LJ, Lee JR. Gastrointestinal pathology in sickle cell disease. Ann Clin Lab Sci 1998; 28: 19-23
4. Shao SH, Orringer EP. Sickle cell intrahepatic cholestasis: approach to a difficult problem. Am J Gastroenterol 1995; 90: 2048-2050
5. Bauer TW, Moore GW, Hutchins GM. The liver in sickle cell disease. A clinicopathologic study of 70 patients. Am J Med 1980; 69: 833-837
6. Schubert TT. Hepatobiliary system in sickle cell disease. Gastroenterology 1986; 90: 2013-2021
7. 7 Hassan M, Hasan S, Giday S, Alamgir L, Banks A, Frederick W, Smoot D, Castro O. Hepatitis C virus in sickle cell disease. J Natl Med Assoc 2003; 95: 939-942
8. DeVault KR, Friedman LS, Westerberg S, Martin P, Hosein B,Ballas SK. Hepatitis C in sickle cell anemia. J Clin Gastroenterol 1994; 18: 206-209
9. Memish ZA, Knawy BA, El-Saed A. Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. Int J Infect Dis 2010; 14: e115-e120
10. Al-Faleh FZ, Sami Ramia, S. Hepatitis C virus (HCV) infection in Saudi Arabia: A review. Ann Saudi Med 1997; 17: 77-82
11. Steinberg MH. Hydroxyurea treatment for sickle cell disease. Scientific World Journal 2002; 2: 1706-1728
12. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651
13. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol 1991; 28: 220-226
14. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52
15. Manns MP, McHutchinson JG, Gordon S. Peginterferon alfa- 2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial. Hepatology 2000; 32: A297-A297
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
17. Swaim MW, Agarwal S, Rosse WF. Successful treatment of hepatitis C in sickle-cell disease. Ann Intern Med 2000; 133: 750-751
18. Ancel DB, Chaslin-Ferbus D, Amiot, XJ. Treatment of chronic hepatitis C in thalassemic and sickle cell disease patients with interferon alfa2b (IFN) and ribavirin (RBV). Los Angeles, CA. DDW 2006: A198
19. Ancel D, Amiot X, Chaslin-Ferbus D, Hagege I, Garioud A, Girot R, Pol S, Grange JD. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol 2009; 21: 726-729
20. Ayyub MA, El-Moursy SA, Khazindar AM, Abbas FA. Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease. Saudi Med J 2009; 30: 712-716
21. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832
22. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol 2001; 38: 14-22
23. Nunez M, Marino A, Miralles C, Berdun MA, Sola J, Hernandez-Burruezo JJ. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictor of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. JAIDS 2007; 45: 439-444
24. Hamidah A, Thambidorai CR, Jamal R. Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-coinfected non-responder to standard interferon-based. Med J Malaysia 2005; 60: 517-519
25. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, Wonke B. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997; 98: 850-855
26. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassemia major. Br J Hematol 2002; 117: 755-758
27. Al-Awamy BH, Niazi GA, el-Mouzan MI, Altorki MT, Naeem MA. Relationship of haemoglobin F and alpha thalassaemia to severity of sickle-cell anaemia in the Eastern Province of Saudi Arabia. Ann Trop Paediatr 1986; 6: 261-265